Getting your player ready...
AspenBio Pharma Inc., developer of a test for appendicitis, gained the most in two months on Nasdaq trading Tuesday after saying the product may reach customers next year. AspenBio jumped $1.77 to $11.42. The company climbed 25 percent in September when Oppenheimer & Co. initiated coverage as a “buy.” The Castle Rock company says its blood test will reduce the number of patients misdiagnosed. The device can identify a protein associated with inflammation of the appendix, said Ron Both, an investor-relations consultant to the company with Liolios Group in Newport Beach, Calif. A test takes about 45 minutes and is expected to cost $200 to $300, Both said. Bloomberg News
